GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mirati Therapeutics Inc (NAS:MRTX) » Definitions » Cyclically Adjusted Revenue per Share

Mirati Therapeutics (Mirati Therapeutics) Cyclically Adjusted Revenue per Share : $0.76 (As of Sep. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Mirati Therapeutics Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Mirati Therapeutics's adjusted revenue per share for the three months ended in Sep. 2023 was $0.252. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.76 for the trailing ten years ended in Sep. 2023.

During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -26.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Mirati Therapeutics was -26.00% per year. The lowest was -33.80% per year. And the median was -29.90% per year.

As of today (2024-05-24), Mirati Therapeutics's current stock price is $58.70. Mirati Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2023 was $0.76. Mirati Therapeutics's Cyclically Adjusted PS Ratio of today is 77.24.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Mirati Therapeutics was 231.20. The lowest was 2.46. And the median was 62.38.


Mirati Therapeutics Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Mirati Therapeutics's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mirati Therapeutics Cyclically Adjusted Revenue per Share Chart

Mirati Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.89 1.78 0.95 0.84 0.72

Mirati Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.76 0.72 0.72 0.74 0.76

Competitive Comparison of Mirati Therapeutics's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Mirati Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mirati Therapeutics's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mirati Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Mirati Therapeutics's Cyclically Adjusted PS Ratio falls into.



Mirati Therapeutics Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Mirati Therapeutics's adjusted Revenue per Share data for the three months ended in Sep. 2023 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=0.252/129.8595*129.8595
=0.252

Current CPI (Sep. 2023) = 129.8595.

Mirati Therapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201312 0.000 98.326 0.000
201403 0.000 99.695 0.000
201406 0.000 100.560 0.000
201409 0.000 100.428 0.000
201412 0.000 99.070 0.000
201503 0.000 99.621 0.000
201506 0.000 100.684 0.000
201509 0.000 100.392 0.000
201512 0.000 99.792 0.000
201603 0.000 100.470 0.000
201606 0.000 101.688 0.000
201609 0.000 101.861 0.000
201612 0.000 101.863 0.000
201703 0.000 102.862 0.000
201706 0.000 103.349 0.000
201709 0.000 104.136 0.000
201712 0.000 104.011 0.000
201803 0.328 105.290 0.405
201806 0.000 106.317 0.000
201809 0.000 106.507 0.000
201812 0.106 105.998 0.130
201903 0.036 107.251 0.044
201906 0.016 108.070 0.019
201909 0.025 108.329 0.030
201912 0.013 108.420 0.016
202003 0.006 108.902 0.007
202006 0.000 108.767 0.000
202009 0.256 109.815 0.303
202012 0.035 109.897 0.041
202103 0.000 111.754 0.000
202106 0.000 114.631 0.000
202109 1.390 115.734 1.560
202112 0.006 117.630 0.007
202203 0.013 121.301 0.014
202206 0.097 125.017 0.101
202209 0.097 125.227 0.101
202212 0.016 125.222 0.017
202303 0.124 127.348 0.126
202306 0.235 128.729 0.237
202309 0.252 129.860 0.252

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Mirati Therapeutics  (NAS:MRTX) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Mirati Therapeutics's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=58.70/0.76
=77.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Mirati Therapeutics was 231.20. The lowest was 2.46. And the median was 62.38.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Mirati Therapeutics Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Mirati Therapeutics's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Mirati Therapeutics (Mirati Therapeutics) Business Description

Industry
Traded in Other Exchanges
Address
3545 Cray Court, San Diego, CA, USA, 92121
Mirati Therapeutics Inc is a clinical-stage oncology company developing novel therapeutics to address the genetic and immunological promoters of cancer. It operates in a single geographical segment being the United States.
Executives
Jamie Christensen officer: Sr. Vice President, Chief Scie C/O MIRATI THERAPEUTICS, INC., 9393 TOWNE CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92121
Benjamin Hickey officer: EVP, Chief Commercial Officer C/O MIRATI THERAPEUTICS, 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA 92121
Aaron Ondrey officer: Interim CFO 3545 CRAY COURT, SAN DIEGO CA 92121
Boxer Capital, Llc other: See remarks 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Christopher Fuglesang other: See remarks 11682 EL CAMINO REAL, SUITE 320, SAN DIEGO CA 92130
Shehan Bharatha Dissanayake other: See remarks 11682 EL CAMINO REAL, SUITE 320, SAN DIEGO CA 92130
Aaron I. Davis other: See remarks 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Mva Investors, Llc other: See remarks 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Boxer Asset Management Inc. other: See remarks CAY HOUSE, EP TAYLOR DRIVE N7776, LYFORD CAY, NEW PROVIDENCE C5 00000
Joseph Lewis other: See remarks PO BOX N7776, LYFORD BAHAMAS
Faheem Hasnain director 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
John B Moriarty officer: Chief Legal Officer ALEXION PHARMACEUTICALS, 352 KNOTTER DRIVE, CHESHIRE CT 06410
Carol Giltner Gallagher director C/O ATARA BIOTHERAPEUTICS, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005
Laurie Stelzer officer: CFO 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Julie M Cherrington director 9393 TOWNE CENTRE DRIVE, STE 200, SAN DIEGO CA 92121

Mirati Therapeutics (Mirati Therapeutics) Headlines

From GuruFocus